Cargando…

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sancho-Saldaña, Agustín, Gil Sánchez, Anna, Quirant-Sánchez, Bibiana, Nogueras, Lara, Peralta, Silvia, Solana, Maria José, González-Mingot, Cristina, Gallego, Yhovanni, Quibus, Laura, Ramo-Tello, Cristina, Presas-Rodríguez, Silvia, Martínez-Cáceres, Eva, Torres, Pascual, Hervás, José Vicente, Valls, Joan, Brieva, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099725/
https://www.ncbi.nlm.nih.gov/pubmed/35566632
http://dx.doi.org/10.3390/jcm11092509
_version_ 1784706677450211328
author Sancho-Saldaña, Agustín
Gil Sánchez, Anna
Quirant-Sánchez, Bibiana
Nogueras, Lara
Peralta, Silvia
Solana, Maria José
González-Mingot, Cristina
Gallego, Yhovanni
Quibus, Laura
Ramo-Tello, Cristina
Presas-Rodríguez, Silvia
Martínez-Cáceres, Eva
Torres, Pascual
Hervás, José Vicente
Valls, Joan
Brieva, Luis
author_facet Sancho-Saldaña, Agustín
Gil Sánchez, Anna
Quirant-Sánchez, Bibiana
Nogueras, Lara
Peralta, Silvia
Solana, Maria José
González-Mingot, Cristina
Gallego, Yhovanni
Quibus, Laura
Ramo-Tello, Cristina
Presas-Rodríguez, Silvia
Martínez-Cáceres, Eva
Torres, Pascual
Hervás, José Vicente
Valls, Joan
Brieva, Luis
author_sort Sancho-Saldaña, Agustín
collection PubMed
description Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26.4% vs. 10.7%, p = 0.006). Although patients taking interferon were significantly older (49.1 vs. 43.5, p = 0.003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2.99 (1.38; 6.36), p = 0.006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT.
format Online
Article
Text
id pubmed-9099725
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90997252022-05-14 Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies Sancho-Saldaña, Agustín Gil Sánchez, Anna Quirant-Sánchez, Bibiana Nogueras, Lara Peralta, Silvia Solana, Maria José González-Mingot, Cristina Gallego, Yhovanni Quibus, Laura Ramo-Tello, Cristina Presas-Rodríguez, Silvia Martínez-Cáceres, Eva Torres, Pascual Hervás, José Vicente Valls, Joan Brieva, Luis J Clin Med Article Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26.4% vs. 10.7%, p = 0.006). Although patients taking interferon were significantly older (49.1 vs. 43.5, p = 0.003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2.99 (1.38; 6.36), p = 0.006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT. MDPI 2022-04-29 /pmc/articles/PMC9099725/ /pubmed/35566632 http://dx.doi.org/10.3390/jcm11092509 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sancho-Saldaña, Agustín
Gil Sánchez, Anna
Quirant-Sánchez, Bibiana
Nogueras, Lara
Peralta, Silvia
Solana, Maria José
González-Mingot, Cristina
Gallego, Yhovanni
Quibus, Laura
Ramo-Tello, Cristina
Presas-Rodríguez, Silvia
Martínez-Cáceres, Eva
Torres, Pascual
Hervás, José Vicente
Valls, Joan
Brieva, Luis
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_full Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_fullStr Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_full_unstemmed Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_short Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_sort seroprevalence of sars-cov-2 in a cohort of patients with multiple sclerosis under disease-modifying therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099725/
https://www.ncbi.nlm.nih.gov/pubmed/35566632
http://dx.doi.org/10.3390/jcm11092509
work_keys_str_mv AT sanchosaldanaagustin seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT gilsanchezanna seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT quirantsanchezbibiana seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT nogueraslara seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT peraltasilvia seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT solanamariajose seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT gonzalezmingotcristina seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT gallegoyhovanni seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT quibuslaura seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT ramotellocristina seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT presasrodriguezsilvia seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT martinezcacereseva seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT torrespascual seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT hervasjosevicente seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT vallsjoan seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies
AT brievaluis seroprevalenceofsarscov2inacohortofpatientswithmultiplesclerosisunderdiseasemodifyingtherapies